Brain Tumor Team

VCS Treatments

Brain Tumors and Neuro-Oncology at Virginia Cancer Specialists

Virginia Cancer Specialists’ (VCS) highly-experienced team of neuro-oncologists and radiation oncologists focus on personalized treatments plans to provide the best possible outcome for each patient and their families. Each member of our team is experienced in caring for people with brain tumors, having had years of specialized training.  Using advanced technologies, leading-edge medical services and treatment options, VCS offers the most advanced, patient-friendly treatment and cancer care.  Because of our participation in innovative clinical trial research programs we are able to offer new treatment options for patients that they wouldn’t normally have access to, right in their own community.

What is Neuro-oncology?

It is the medical terminology for the specialty treating malignancies of the brain and spinal cord. Neuro-oncologists treat patients with primary brain tumors and metastasis to the brain or spinal fluid, as well as neurological complications of cancer. Such complications can include seizures, cerebral edema, stroke, and peripheral nerve disorders.

VCS offers the most advanced, patient-friendly Brain Tumor treatment and cancer care

How are Brain Tumors classified; according to grade from I-IV

Grade I tumors are often considered benign and tend to grow slowly.  The brain tissue is similar to normal brain cells. Grade II tumors are malignant and the cells look less like normal brain cells than Grade I.  In grade III tumors, the malignant cells look very different than normal cells, and grow rapidly, referred to as anaplastic. Grade IV tumors have the most abnormal appearance and tend to grow the most rapidly and are usually the most aggressive.  Grades I-II tumors are considered low grade, while Grades III-IV are considered high grade.

There are two major categories of brain tumors, primary brain tumors, which start in the brain and rarely spread outside the nervous system, and metastatic brain tumors, which develop in other parts of the body (for example, breast, lung, skin) and spread to the brain.


Metastatic tumors are the most commonly occurring brain tumors, with an incidence rate 10 times greater than primary brain tumors.  These include:

  • Gliomas are the most common class of primary brain tumor and are formed from the glial cells that provide structural support for the neurons (the thinking cells in the brain). The more common gliomas include:
  • Astrocytomas are the most common type of glioma and are graded I, II, III, or IV. The most common and aggressive form is grade IV astrocytoma, also known as glioblastoma multiforme, or GBM. All forms of astrocytoma can develop anywhere in the central nervous system.
  • Ependymomas develop in the hollow cavities of the brain or in the spinal cord and are often benign and slow growing.
  • Oligodendrogliomas originate in the cells that provide support for the connection “wires” between neurons.

There are also many types of non-glial brain tumors; however, most are rare:

  • Craniopharyngiomas develop in the pituitary gland region, most often in children and adolescents.
  • Meningiomas occur in the membranes protecting the brain and spinal cord and are usually slow growing and benign. Malignant meningiomas are less common, but grow more quickly.
  • Pineal tumors are found near the center of the brain and are difficult to completely remove.


There are many types of brain tumors that are named based on the type of brain cells they originated from.  Most primary brain tumors begin from glial cells in the brain and are called gliomas. One type of glioma is an astrocytoma, which can be any grade. Grade I-II astrocytomas are often called a low grade glioma. A grade III astrocytoma is sometimes called an anaplastic astrocytoma, while a grade IV may be called a glioblastoma.

Meningiomas are tumors that arise from the brain’s meninges and can be grade I-III, though are usually grade I and tend to grow slowly.  Oligodenrogliomas come from the cells that surround and protect nerves. These can be Grade II–III.

At this time we still don’t know what causes most brain tumors. There are some rare cases of brain tumors running in families though the vast majority of brain tumors are not related to family genetics. There continues to be ongoing research into areas such as cell phone use, head injury, and chemical use to evaluate for a link, though so far there have not been any consistent results that show a cause.

The symptoms of a brain tumor can vary from person to person. They may include headache, visual changes, seizures, weakness or changes in mood or memory, to name a few.

Brain tumors are often treated differently depending on the type, location and grade of tumor. These options may include surgery, radiation therapy and chemotherapy.  Surgery is usually the first treatment, and may involve removing all or part of the tumor. Depending on the grade and type of tumor, location as well as the patient’s age and overall health, this may be followed by additional treatment. This may include both radiation and chemotherapy.  Radiation and chemotherapy are often given in combination following surgery for a period of several weeks. This may be followed by chemotherapy alone for a period of time. Depending on the type of chemotherapy, this may be given as either oral medication or intravenously.

While being treated, patients will typically have regular monitoring with frequent MRI’s of the brain as well as regular follow up with their doctors including surgeons, radiation and medical oncologists.  We continue to learn more and more through research and clinical trials into the various types of brain tumors. This research has led to improved treatments that are helping patients to live longer and with a better quality of life than ever before.

Tumor Profiling

While tumor tissue biopsy and the tumor’s appearance under the microscope is still the standard of care for diagnosing and naming brain tumors, deeper knowledge of the molecular underpinnings of a tumor’s DNA can help direct treatments and improve outcomes. To better define a tumor’s behavior and for choosing possible targets for therapy, physicians now profile most patients’ tumor’s DNA to identify the driver mutations. Even among patients with the same type of cancer, the behavior of the cancer and its response to treatment can vary widely, based on these genetic changes.

It is increasingly clear that specific characteristics of cancer cells and cancer patients can have a profound impact on prognosis and treatment outcome. Targeted therapies are based on the type of tumor and its profile. Although factoring these characteristics into treatment decisions makes cancer care more complex, it also offers the promise of improved outcomes. Targeted therapies for each tumor lead to better outcomes through personalized medicine.

Treating Brain Tumors

Treatment for brain tumors is determined by many factors, including tumor type; grade; size and location in the brain; whether it’s newly diagnosed or a recurrence; the tumor’s specific genetic makeup; and your overall health. The potential benefits of a singular or combination of treatments or participation in a clinical trial must be carefully balanced with the potential risks.


Surgery is an important treatment for most brain tumors. This is especially true if located within the membranes covering the brain or in an area where removal would not damage the surrounding areas. Even if the entire tumor cannot be removed, surgery can relieve some symptoms caused by the tumor. Many benign tumors are treated only by surgery.

Most malignant tumors also require treatment after surgery such as radiation therapy, chemotherapy, electrical field therapy, or targeted drug therapy.

    [0] => Array
            [acf_fc_layout] => physician_information
            [title] => Our Brain Tumor Team
            [display_all] => 1
            [stretch_to_fit] => 1
            [hide_search] => 1
            [add_url_to_image] => 1
            [manual_sorting] => 
            [physicians] => Array
                    [0] => WP_Post Object
                            [ID] => 521
                            [post_author] => 2
                            [post_date] => 2017-09-07 17:39:41
                            [post_date_gmt] => 2017-09-07 17:39:41
                            [post_content] => Dr. Timothy A. McCarthy graduated with high honors from Rutgers University where he received a Bachelor of Science in Materials Engineering.  He then went on to earn his medical degree and complete an Internal Medicine residency at Rutgers Robert Wood Johnson Medical School.  During his residency, Dr. McCarthy was honored with the Nilesh Tamakuwala, MD Memorial Award, a distinction presented to the individual who best demonstrated compassion in care and excellence in teaching.

Board-certified in Medical Oncology, Hematology and Internal Medicine, Dr. McCarthy completed his fellowship in Medical Oncology and Hematology at University of North Carolina Hospitals.  As an Oncology Fellow, Dr. McCarthy took a leadership role working with various departments with a specific interest in quality and process improvement projects.  Dr. McCarthy is a published author and has presented posters at various medical events, including the annual American Society of Clinical Oncology (ASCO) symposium.

Outside of medicine, Dr. McCarthy enjoys staying active and exploring the outdoors with his wife and 3 young children. He also enjoys listening to a diverse array of music and plays several different instruments.

[post_title] => Timothy A. McCarthy, M.D. [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => timothy-a-mccarthy-m-d [to_ping] => [pinged] => [post_modified] => 2019-01-23 14:31:58 [post_modified_gmt] => 2019-01-23 14:31:58 [post_content_filtered] => [post_parent] => 0 [guid] => [menu_order] => 0 [post_type] => physician [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 529 [post_author] => 2 [post_date] => 2017-09-07 18:21:32 [post_date_gmt] => 2017-09-07 18:21:32 [post_content] => Dr. Patel-Donnelly is triple board-certified in medical oncology, hematology, and internal medicine. She completed her fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her Doctorate of Medicine and completed her Internal Medicine Internship and Residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York. Dr. Patel-Donnelly has taken an active role at Virginia Cancer Specialists and in the local and medical communities. Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology, and the Medical Society of Virginia. Focusing on a special interest in hematologic malignancies, brain tumors, and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and has served as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and has held a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University. Dr. Patel-Donnelly has also received multiple awards and honors which include the Harvard Partners in Excellence Award, Leukemia and Lymphoma Society’s “Relentless for a Cure” award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, NASE Achievement Scholarship, and Distinguished Honors and Independent Research in Biochemistry. Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian magazine. Additionally, she has been listed as a “Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor”. Dr. Patel-Donnelly is a published author and has spoken both at local educational events and at national and local news interviews. Dr. Patel-Donnelly is a member of several, prestigious, national committees. She is on the highly-selective, national panel tasked with writing Oncology Board questions for the American Board of Internal Medicine, which certifies that medical oncologists have a competent fund of knowledge to be board-certified and practice. She has also been selected to serve on the American Society of Clinical Oncology (ASCO) Leukemia Guideline Committee, which reviews current research evidence and makes uniform guidelines on treating leukemia. Dr. Patel-Donnelly is currently an Assistant Professor, in the Department of Oncology at Johns Hopkins University. Dr. Patel-Donnelly lives in Northern Virginia with her husband and two children. She enjoys spending time with her family, cooking, running, traveling, and reading.
  [post_title] => Dipti Patel-Donnelly, M.D. [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dipti-patel-donnelly-m-d [to_ping] => [pinged] => [post_modified] => 2019-03-11 20:03:44 [post_modified_gmt] => 2019-03-11 20:03:44 [post_content_filtered] => [post_parent] => 0 [guid] => [menu_order] => 0 [post_type] => physician [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 543 [post_author] => 2 [post_date] => 2017-09-08 14:33:05 [post_date_gmt] => 2017-09-08 14:33:05 [post_content] => Dr. Gregory S. Sibley joined Virginia Cancer Specialists after 14 years in Radiation Oncology at Sibley Memorial Hospital in Washington, D.C.  Throughout his career, Dr. Sibley has focused on providing the highest quality care in the field of radiation oncology. He has positioned himself as an expert in the multi-disciplinary treatment of cancer and in state-of-the-art radiation treatment planning techniques. Within the US Oncology Network, Dr. Sibley is a member of the Executive Committee for Radiation Oncology and Vice-Chair for the Technology Committee. Dr. Sibley has authored over 20 peer-reviewed publications, many while on faculty at Duke University Medical Center. Although well-versed in the treatment of multiple cancers, Dr. Sibley has special interest in breast cancer, brachytherapy for prostate cancer, and intensity-modulated radiotherapy for head and neck, and lung cancers. In his spare time, Dr. Sibley is an avid hockey player and triathlete.
[post_title] => Gregory S. Sibley, M.D. [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gregory-s-sibley-m-d [to_ping] => [pinged] => [post_modified] => 2019-03-12 12:50:49 [post_modified_gmt] => 2019-03-12 12:50:49 [post_content_filtered] => [post_parent] => 0 [guid] => [menu_order] => 0 [post_type] => physician [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [page_builder] => 1 [index] => 0 ) )

Our Brain Tumor Team

Radiation Therapy

Radiation therapy is often used to treat brain cancer. It may be used alone or in combination with surgery and/or chemotherapy to treat primary or metastatic brain tumors.

  • External Beam Radiation Therapy uses high-energy X-ray beams (photons) delivered by a linear accelerator and aimed at specific points within the nervous system. Intensity-modulated radiotherapy planning is typically utilized to deliver a highly conformal dose to the target volume, while maximally sparing normal tissues.
  • Stereotactic radiosurgery (SRS) is a highly focused external beam radiotherapy delivered in one to five treatments. This is a non-surgical procedure that delivers precisely-targeted radiation at much higher doses than traditional radiation therapy with minimal damage to surrounding healthy tissue. This technique is primarily used for benign tumors and metastases.
  • Proton Beam Radiation delivers high-energy proton beams directly to tumors with very little exit dose beyond the target, minimizing damage to surrounding healthy tissue.


Virginia Cancer Specialists provides brain tumor patients access to cancer therapies and the latest investigational drugs through participation in clinical trials in all phases of development (from Phase I and on). These new treatments may result in shrinking the tumor or alleviating symptoms.

Helpful Resources

Visit one of the helpful links below for more information:

Clinical Trials